The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV ...

Higher intakes of diet beverages and/or saccharin are associated with an increased risk of developing diabetes over the long ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

IntegriMedical has introduced a needle-free injection system (N-FIS) that eliminates the need for any prick or piercing, ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

The analyst informs investors that the business recently released positive topline data from the phase 3 ORIGIN study of ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN) ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.